Share Price and Basic Stock Data
Last Updated: October 18, 2025, 7:56 pm
PEG Ratio | 0.00 |
---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Caprolactam Chemicals Ltd operates in the Chemicals – Inorganic – Caustic Soda/Soda Ash sector, with a market capitalization of ₹20.9 Cr. The company’s share price currently stands at ₹45.5. Revenue trends reveal significant fluctuations; sales recorded ₹0.63 Cr in Mar 2022, which surged to ₹9.84 Cr in Mar 2023, before declining to ₹6.74 Cr in Mar 2025. Quarterly sales have also shown a downward trajectory post-June 2023, with the latest quarter (Dec 2024) reporting ₹2.29 Cr. The company has experienced varying operational performance, with operating profit margins (OPM) peaking at 58.18% in Jun 2022 but declining to 14.29% by Mar 2025. The company’s cash conversion cycle (CCC) stood at 144.54 days, indicating challenges in managing working capital efficiently. These trends reflect a volatile revenue stream, likely impacted by market conditions and operational inefficiencies.
Profitability and Efficiency Metrics
Caprolactam Chemicals Ltd has faced challenges in profitability, as evidenced by its net profit of -₹0.71 Cr for the year ending Mar 2025. This negative profit reflects a concerning trend, given that the company reported a net profit of ₹2.55 Cr in Mar 2023. The operating profit margin (OPM) has also seen significant fluctuations, with highs of 58.18% in Jun 2022 followed by a decrease to 14.29% in Mar 2025. Return on equity (ROE) is reported at 13.7%, while return on capital employed (ROCE) is notably low at 0.48%. The interest coverage ratio (ICR) improved to 2.44 times, indicating a better ability to meet interest obligations compared to prior periods. However, profitability remains a critical area for improvement, especially as the company navigates a highly competitive market.
Balance Sheet Strength and Financial Ratios
The balance sheet of Caprolactam Chemicals Ltd reveals a concerning trend in terms of liabilities and equity. The company’s total borrowings stood at ₹8.72 Cr, against reserves of merely ₹0.23 Cr, leading to a total debt-to-equity ratio of 1.80. This high leverage indicates potential financial risk, particularly in a sector where capital requirements can be significant. The current ratio is reported at 0.38, and the quick ratio at 0.34, both below the industry average, suggesting liquidity challenges. The company reported a book value per share of ₹10.50, which, when compared to its trading price, indicates a price-to-book ratio of 4.21x. Such a high ratio could imply overvaluation relative to its net assets. Strengthening the balance sheet through improved profitability and effective debt management is essential for the company’s financial health moving forward.
Shareholding Pattern and Investor Confidence
Caprolactam Chemicals Ltd has a diverse shareholding structure, with promoters holding 54.04% of the stake, reflecting a strong management commitment. The public holds 45.95%, and the company reported a total of 8,158 shareholders as of Mar 2025. This distribution indicates a stable ownership structure, which could inspire investor confidence. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may limit the stock’s liquidity and broader market appeal. The steady increase in promoter shareholding over recent quarters, from 52.37% in Sep 2022 to 54.04% in Mar 2025, suggests that management is likely optimistic about the company’s future. Nonetheless, the lack of institutional backing could raise concerns regarding the stock’s perceived risk and investment attractiveness.
Outlook, Risks, and Final Insight
Looking ahead, Caprolactam Chemicals Ltd faces both opportunities and risks. If margins sustain an upward trajectory alongside improved sales, the company could see a turnaround in profitability. However, persistent operational inefficiencies and high borrowings pose significant risks that could hinder growth. The company’s ability to manage its cash conversion cycle effectively remains critical, especially given the current liquidity ratios. If the management can address these issues, including enhancing operational efficiencies and reducing debt levels, there may be potential for recovery in profitability and investor sentiment. The company’s strong promoter backing may provide a buffer during challenging times, but the lack of institutional support could limit its capital-raising capabilities. Thus, a focused strategy on operational improvements and financial management is essential for Caprolactam Chemicals Ltd to navigate the competitive landscape successfully.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Caprolactam Chemicals Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
Caprolactam Chemicals Ltd | 19.3 Cr. | 42.0 | 65.0/37.5 | 10.5 | 0.00 % | 0.48 % | 13.7 % | 10.0 | |
Standard Industries Ltd | 122 Cr. | 19.0 | 31.1/17.4 | 18.6 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
Gujarat Alkalies & Chemicals Ltd | 4,007 Cr. | 546 | 894/484 | 772 | 2.90 % | 0.34 % | 1.13 % | 10.0 | |
GHCL Ltd | 6,013 Cr. | 626 | 779/511 | 9.74 | 364 | 1.92 % | 24.2 % | 18.6 % | 10.0 |
Tata Chemicals Ltd | 22,997 Cr. | 903 | 1,247/756 | 54.5 | 847 | 1.22 % | 3.96 % | 1.20 % | 10.0 |
Industry Average | 6,793.40 Cr | 452.00 | 38.35 | 382.68 | 1.04% | 7.11% | 8.14% | 9.17 |
Quarterly Result
Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 0.63 | 2.75 | 2.51 | 2.37 | 2.22 | 2.06 | 1.97 | 1.49 | 1.44 | 1.12 | 1.71 | 2.29 | 1.61 |
Expenses | 0.55 | 1.15 | 1.24 | 1.28 | 1.51 | 1.30 | 1.52 | 1.20 | 0.77 | 0.87 | 1.14 | 1.82 | 1.38 |
Operating Profit | 0.08 | 1.60 | 1.27 | 1.09 | 0.71 | 0.76 | 0.45 | 0.29 | 0.67 | 0.25 | 0.57 | 0.47 | 0.23 |
OPM % | 12.70% | 58.18% | 50.60% | 45.99% | 31.98% | 36.89% | 22.84% | 19.46% | 46.53% | 22.32% | 33.33% | 20.52% | 14.29% |
Other Income | 0.16 | 0.01 | 0.01 | 0.00 | -0.01 | 0.15 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.01 | 0.00 |
Interest | 0.06 | 0.13 | 0.14 | 0.14 | 0.15 | 0.14 | 0.13 | 0.11 | 0.12 | 0.14 | 0.14 | 0.17 | 0.18 |
Depreciation | 0.31 | 0.22 | 0.22 | 0.33 | 0.39 | 0.37 | 0.39 | 0.40 | 0.42 | 0.38 | 0.40 | 0.40 | 0.41 |
Profit before tax | -0.13 | 1.26 | 0.92 | 0.62 | 0.16 | 0.40 | -0.07 | -0.22 | 0.16 | -0.27 | 0.03 | -0.09 | -0.36 |
Tax % | -107.69% | 24.60% | 25.00% | -17.74% | 0.00% | 25.00% | -28.57% | -31.82% | 31.25% | 0.00% | 0.00% | -66.67% | 25.00% |
Net Profit | 0.02 | 0.95 | 0.69 | 0.74 | 0.17 | 0.30 | -0.06 | -0.16 | 0.12 | -0.27 | 0.04 | -0.03 | -0.45 |
EPS in Rs | 0.04 | 2.07 | 1.50 | 1.61 | 0.37 | 0.65 | -0.13 | -0.35 | 0.26 | -0.59 | 0.09 | -0.07 | -0.98 |
Last Updated: May 31, 2025, 6:36 am
Below is a detailed analysis of the quarterly data for Caprolactam Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 1.61 Cr.. The value appears to be declining and may need further review. It has decreased from 2.29 Cr. (Dec 2024) to 1.61 Cr., marking a decrease of 0.68 Cr..
- For Expenses, as of Mar 2025, the value is 1.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.82 Cr. (Dec 2024) to 1.38 Cr., marking a decrease of 0.44 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.23 Cr.. The value appears to be declining and may need further review. It has decreased from 0.47 Cr. (Dec 2024) to 0.23 Cr., marking a decrease of 0.24 Cr..
- For OPM %, as of Mar 2025, the value is 14.29%. The value appears to be declining and may need further review. It has decreased from 20.52% (Dec 2024) to 14.29%, marking a decrease of 6.23%.
- For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.01 Cr. (Dec 2024) to 0.00 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.17 Cr. (Dec 2024) to 0.18 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Mar 2025, the value is 0.41 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.40 Cr. (Dec 2024) to 0.41 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Mar 2025, the value is -0.36 Cr.. The value appears to be declining and may need further review. It has decreased from -0.09 Cr. (Dec 2024) to -0.36 Cr., marking a decrease of 0.27 Cr..
- For Tax %, as of Mar 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from -66.67% (Dec 2024) to 25.00%, marking an increase of 91.67%.
- For Net Profit, as of Mar 2025, the value is -0.45 Cr.. The value appears to be declining and may need further review. It has decreased from -0.03 Cr. (Dec 2024) to -0.45 Cr., marking a decrease of 0.42 Cr..
- For EPS in Rs, as of Mar 2025, the value is -0.98. The value appears to be declining and may need further review. It has decreased from -0.07 (Dec 2024) to -0.98, marking a decrease of 0.91.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:42 am
Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 3.92 | 2.85 | 4.88 | 3.23 | 4.07 | 5.19 | 6.51 | 6.31 | 2.07 | 9.84 | 6.96 | 6.74 | 8.17 |
Expenses | 4.03 | 2.46 | 4.05 | 2.76 | 3.18 | 3.31 | 3.99 | 4.14 | 2.64 | 5.17 | 4.79 | 5.22 | 5.85 |
Operating Profit | -0.11 | 0.39 | 0.83 | 0.47 | 0.89 | 1.88 | 2.52 | 2.17 | -0.57 | 4.67 | 2.17 | 1.52 | 2.32 |
OPM % | -2.81% | 13.68% | 17.01% | 14.55% | 21.87% | 36.22% | 38.71% | 34.39% | -27.54% | 47.46% | 31.18% | 22.55% | 28.40% |
Other Income | 0.01 | -0.15 | 0.40 | 0.01 | 0.07 | 0.07 | 0.06 | 0.09 | 0.41 | 0.02 | 0.18 | 0.01 | 0.01 |
Interest | 0.00 | 0.06 | 0.11 | 0.12 | 0.19 | 0.34 | 0.30 | 0.30 | 0.28 | 0.57 | 0.50 | 0.63 | 0.67 |
Depreciation | 0.19 | 0.23 | 0.51 | 0.47 | 0.57 | 0.97 | 1.02 | 1.07 | 1.03 | 1.15 | 1.58 | 1.59 | 1.59 |
Profit before tax | -0.29 | -0.05 | 0.61 | -0.11 | 0.20 | 0.64 | 1.26 | 0.89 | -1.47 | 2.97 | 0.27 | -0.69 | 0.07 |
Tax % | -6.90% | 0.00% | 14.75% | 0.00% | 15.00% | 23.44% | 24.60% | 26.97% | -12.93% | 14.14% | 29.63% | 4.35% | |
Net Profit | -0.27 | -0.06 | 0.52 | -0.12 | 0.17 | 0.50 | 0.95 | 0.65 | -1.28 | 2.55 | 0.20 | -0.71 | -0.08 |
EPS in Rs | -0.59 | -0.13 | 1.13 | -0.26 | 0.37 | 1.09 | 2.07 | 1.41 | -2.78 | 5.54 | 0.43 | -1.54 | -0.18 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
---|---|---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | 77.78% | 966.67% | -123.08% | 241.67% | 194.12% | 90.00% | -31.58% | -296.92% | 299.22% | -92.16% | -455.00% |
Change in YoY Net Profit Growth (%) | 0.00% | 888.89% | -1089.74% | 364.74% | -47.55% | -104.12% | -121.58% | -265.34% | 596.14% | -391.38% | -362.84% |
Caprolactam Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 1% |
3 Years: | 48% |
TTM: | 36% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 13% |
TTM: | 78% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 23% |
3 Years: | -9% |
1 Year: | -12% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 6% |
3 Years: | 14% |
Last Year: | -14% |
Last Updated: September 5, 2025, 2:51 pm
Balance Sheet
Last Updated: September 10, 2025, 3:18 pm
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4.59 | 4.59 | 4.59 | 4.59 | 4.59 | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 |
Reserves | -3.08 | -3.13 | -2.61 | -2.73 | -2.56 | -2.06 | -1.10 | -0.52 | -1.80 | 0.74 | 0.95 | 0.23 |
Borrowings | 0.09 | 0.82 | 0.95 | 1.37 | 1.89 | 3.58 | 2.45 | 2.15 | 3.76 | 5.69 | 5.86 | 8.72 |
Other Liabilities | 0.52 | 1.15 | 0.98 | 1.10 | 2.35 | 1.29 | 1.16 | 0.97 | 3.77 | 0.49 | 0.25 | 0.74 |
Total Liabilities | 2.12 | 3.43 | 3.91 | 4.33 | 6.27 | 7.41 | 7.11 | 7.20 | 10.33 | 11.52 | 11.66 | 14.29 |
Fixed Assets | 1.19 | 2.92 | 2.96 | 3.38 | 3.56 | 6.37 | 6.07 | 5.50 | 5.26 | 10.22 | 10.29 | 10.31 |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.96 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Assets | 0.93 | 0.51 | 0.95 | 0.95 | 2.71 | 1.04 | 1.04 | 1.70 | 1.11 | 1.30 | 1.37 | 3.98 |
Total Assets | 2.12 | 3.43 | 3.91 | 4.33 | 6.27 | 7.41 | 7.11 | 7.20 | 10.33 | 11.52 | 11.66 | 14.29 |
Below is a detailed analysis of the balance sheet data for Caprolactam Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 4.60 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.60 Cr..
- For Reserves, as of Mar 2025, the value is 0.23 Cr.. The value appears to be declining and may need further review. It has decreased from 0.95 Cr. (Mar 2024) to 0.23 Cr., marking a decrease of 0.72 Cr..
- For Borrowings, as of Mar 2025, the value is 8.72 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 5.86 Cr. (Mar 2024) to 8.72 Cr., marking an increase of 2.86 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.74 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.25 Cr. (Mar 2024) to 0.74 Cr., marking an increase of 0.49 Cr..
- For Total Liabilities, as of Mar 2025, the value is 14.29 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.66 Cr. (Mar 2024) to 14.29 Cr., marking an increase of 2.63 Cr..
- For Fixed Assets, as of Mar 2025, the value is 10.31 Cr.. The value appears strong and on an upward trend. It has increased from 10.29 Cr. (Mar 2024) to 10.31 Cr., marking an increase of 0.02 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 3.98 Cr.. The value appears strong and on an upward trend. It has increased from 1.37 Cr. (Mar 2024) to 3.98 Cr., marking an increase of 2.61 Cr..
- For Total Assets, as of Mar 2025, the value is 14.29 Cr.. The value appears strong and on an upward trend. It has increased from 11.66 Cr. (Mar 2024) to 14.29 Cr., marking an increase of 2.63 Cr..
However, the Borrowings (8.72 Cr.) are higher than the Reserves (0.23 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | -0.20 | -0.43 | -0.12 | -0.90 | -1.00 | -1.70 | 0.07 | 0.02 | -4.33 | -1.02 | -3.69 | -7.20 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 25.14 | 1.28 | 38.89 | 40.68 | 69.05 | 2.81 | 16.82 | 27.19 | 5.29 | 25.22 | 33.56 | 152.72 |
Inventory Days | 104.29 | 304.17 | 88.78 | 82.64 | 53.85 | 52.14 | 111.68 | |||||
Days Payable | 43.45 | 861.81 | 799.05 | 344.34 | 173.52 | 111.73 | 119.85 | |||||
Cash Conversion Cycle | 85.97 | 1.28 | 38.89 | 40.68 | -488.58 | -707.46 | 16.82 | 27.19 | -256.41 | -94.45 | -26.03 | 144.54 |
Working Capital Days | 20.48 | -189.54 | -71.80 | -169.50 | -232.27 | -274.28 | -158.11 | -106.43 | -689.44 | -94.22 | -267.46 | -314.64 |
ROCE % | -17.06% | 11.34% | 27.64% | 0.32% | 10.91% | 19.52% | 25.85% | 19.54% | -18.61% | 40.25% | 6.86% | -0.48% |
This stock is not held by any mutual fund.
Key Financial Ratios
Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
---|---|---|---|---|---|
FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Basic EPS (Rs.) | -1.54 | 0.43 | 5.54 | -2.79 | 1.41 |
Diluted EPS (Rs.) | -1.54 | 0.43 | 5.54 | -2.79 | 1.41 |
Cash EPS (Rs.) | 1.91 | 3.87 | 8.05 | -0.53 | 3.73 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 10.50 | 12.06 | 11.61 | 6.08 | 8.87 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 10.50 | 12.06 | 11.61 | 6.08 | 8.87 |
Revenue From Operations / Share (Rs.) | 14.65 | 15.12 | 21.39 | 4.50 | 13.72 |
PBDIT / Share (Rs.) | 3.33 | 5.11 | 10.20 | -0.35 | 4.90 |
PBIT / Share (Rs.) | -0.11 | 1.67 | 7.69 | -2.60 | 2.58 |
PBT / Share (Rs.) | -1.49 | 0.59 | 6.46 | -3.20 | 1.94 |
Net Profit / Share (Rs.) | -1.54 | 0.42 | 5.54 | -2.79 | 1.41 |
PBDIT Margin (%) | 22.75 | 33.81 | 47.66 | -7.87 | 35.72 |
PBIT Margin (%) | -0.81 | 11.07 | 35.95 | -57.88 | 18.83 |
PBT Margin (%) | -10.14 | 3.91 | 30.18 | -71.24 | 14.12 |
Net Profit Margin (%) | -10.51 | 2.83 | 25.89 | -61.97 | 10.31 |
Return on Networth / Equity (%) | -14.67 | 3.55 | 47.70 | -45.82 | 15.94 |
Return on Capital Employeed (%) | -1.12 | 10.62 | 44.09 | -21.52 | 29.13 |
Return On Assets (%) | -4.96 | 1.69 | 22.12 | -12.40 | 9.30 |
Long Term Debt / Equity (X) | 0.00 | 0.29 | 0.49 | 0.98 | 0.00 |
Total Debt / Equity (X) | 1.80 | 1.06 | 1.06 | 1.34 | 0.52 |
Asset Turnover Ratio (%) | 0.51 | 0.60 | 0.90 | 0.23 | 0.90 |
Current Ratio (X) | 0.38 | 0.24 | 0.34 | 0.21 | 0.53 |
Quick Ratio (X) | 0.34 | 0.22 | 0.31 | 0.18 | 0.50 |
Inventory Turnover Ratio (X) | 28.47 | 6.31 | 5.53 | 4.83 | 0.13 |
Interest Coverage Ratio (X) | 2.44 | 4.73 | 8.26 | -0.58 | 7.58 |
Interest Coverage Ratio (Post Tax) (X) | -0.12 | 1.40 | 5.49 | -3.64 | 3.19 |
Enterprise Value (Cr.) | 28.94 | 29.47 | 29.54 | 25.41 | 16.72 |
EV / Net Operating Revenue (X) | 4.29 | 4.24 | 3.00 | 12.28 | 2.65 |
EV / EBITDA (X) | 18.88 | 12.53 | 6.30 | -156.02 | 7.42 |
MarketCap / Net Operating Revenue (X) | 3.01 | 3.40 | 2.45 | 10.54 | 2.39 |
Price / BV (X) | 4.21 | 4.27 | 4.51 | 7.79 | 3.70 |
Price / Net Operating Revenue (X) | 3.01 | 3.41 | 2.45 | 10.54 | 2.39 |
EarningsYield | -0.03 | 0.01 | 0.10 | -0.05 | 0.04 |
After reviewing the key financial ratios for Caprolactam Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 5. It has decreased from 0.43 (Mar 24) to -1.54, marking a decrease of 1.97.
- For Diluted EPS (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 5. It has decreased from 0.43 (Mar 24) to -1.54, marking a decrease of 1.97.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.91. This value is below the healthy minimum of 3. It has decreased from 3.87 (Mar 24) to 1.91, marking a decrease of 1.96.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.50. It has decreased from 12.06 (Mar 24) to 10.50, marking a decrease of 1.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.50. It has decreased from 12.06 (Mar 24) to 10.50, marking a decrease of 1.56.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 14.65. It has decreased from 15.12 (Mar 24) to 14.65, marking a decrease of 0.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.33. This value is within the healthy range. It has decreased from 5.11 (Mar 24) to 3.33, marking a decrease of 1.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.11. This value is below the healthy minimum of 0. It has decreased from 1.67 (Mar 24) to -0.11, marking a decrease of 1.78.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.49. This value is below the healthy minimum of 0. It has decreased from 0.59 (Mar 24) to -1.49, marking a decrease of 2.08.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 2. It has decreased from 0.42 (Mar 24) to -1.54, marking a decrease of 1.96.
- For PBDIT Margin (%), as of Mar 25, the value is 22.75. This value is within the healthy range. It has decreased from 33.81 (Mar 24) to 22.75, marking a decrease of 11.06.
- For PBIT Margin (%), as of Mar 25, the value is -0.81. This value is below the healthy minimum of 10. It has decreased from 11.07 (Mar 24) to -0.81, marking a decrease of 11.88.
- For PBT Margin (%), as of Mar 25, the value is -10.14. This value is below the healthy minimum of 10. It has decreased from 3.91 (Mar 24) to -10.14, marking a decrease of 14.05.
- For Net Profit Margin (%), as of Mar 25, the value is -10.51. This value is below the healthy minimum of 5. It has decreased from 2.83 (Mar 24) to -10.51, marking a decrease of 13.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is -14.67. This value is below the healthy minimum of 15. It has decreased from 3.55 (Mar 24) to -14.67, marking a decrease of 18.22.
- For Return on Capital Employeed (%), as of Mar 25, the value is -1.12. This value is below the healthy minimum of 10. It has decreased from 10.62 (Mar 24) to -1.12, marking a decrease of 11.74.
- For Return On Assets (%), as of Mar 25, the value is -4.96. This value is below the healthy minimum of 5. It has decreased from 1.69 (Mar 24) to -4.96, marking a decrease of 6.65.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.29 (Mar 24) to 0.00, marking a decrease of 0.29.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.80. This value exceeds the healthy maximum of 1. It has increased from 1.06 (Mar 24) to 1.80, marking an increase of 0.74.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.51. It has decreased from 0.60 (Mar 24) to 0.51, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 1.5. It has increased from 0.24 (Mar 24) to 0.38, marking an increase of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.34, marking an increase of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 28.47. This value exceeds the healthy maximum of 8. It has increased from 6.31 (Mar 24) to 28.47, marking an increase of 22.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.44. This value is below the healthy minimum of 3. It has decreased from 4.73 (Mar 24) to 2.44, marking a decrease of 2.29.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.12. This value is below the healthy minimum of 3. It has decreased from 1.40 (Mar 24) to -0.12, marking a decrease of 1.52.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28.94. It has decreased from 29.47 (Mar 24) to 28.94, marking a decrease of 0.53.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.29. This value exceeds the healthy maximum of 3. It has increased from 4.24 (Mar 24) to 4.29, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 25, the value is 18.88. This value exceeds the healthy maximum of 15. It has increased from 12.53 (Mar 24) to 18.88, marking an increase of 6.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.40 (Mar 24) to 3.01, marking a decrease of 0.39.
- For Price / BV (X), as of Mar 25, the value is 4.21. This value exceeds the healthy maximum of 3. It has decreased from 4.27 (Mar 24) to 4.21, marking a decrease of 0.06.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.41 (Mar 24) to 3.01, marking a decrease of 0.40.
- For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.03, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Caprolactam Chemicals Ltd:
- Net Profit Margin: -10.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -1.12% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -14.67% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.12
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.34
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 38.35)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.8
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -10.51%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Chemicals - Inorganic - Caustic Soda/Soda Ash | B-31, MIDC, Mahad, Raigad District Maharashtra 402302 | caprolactam@gmail.com http://www.caprolactam.com |
Management | |
---|---|
Name | Position Held |
Mrs. Zaver Shankarlal Bhanushali | Chairperson & Managing Director |
Mr. Siddharth Shankarlal Bhanushali | WholeTime Director & CFO |
Mr. Viren Jaysukhlal Jasani | Ind. Non-Executive Director |
Mr. Kamlesh Damji Joisher | Ind. Non-Executive Director |
Mrs. Poonam Bhavin Bhanushali | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Caprolactam Chemicals Ltd?
Caprolactam Chemicals Ltd's intrinsic value (as of 18 October 2025) is 17.61 which is 58.07% lower the current market price of 42.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 19.3 Cr. market cap, FY2025-2026 high/low of 65.0/37.5, reserves of ₹0.23 Cr, and liabilities of 14.29 Cr.
What is the Market Cap of Caprolactam Chemicals Ltd?
The Market Cap of Caprolactam Chemicals Ltd is 19.3 Cr..
What is the current Stock Price of Caprolactam Chemicals Ltd as on 18 October 2025?
The current stock price of Caprolactam Chemicals Ltd as on 18 October 2025 is 42.0.
What is the High / Low of Caprolactam Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Caprolactam Chemicals Ltd stocks is 65.0/37.5.
What is the Stock P/E of Caprolactam Chemicals Ltd?
The Stock P/E of Caprolactam Chemicals Ltd is .
What is the Book Value of Caprolactam Chemicals Ltd?
The Book Value of Caprolactam Chemicals Ltd is 10.5.
What is the Dividend Yield of Caprolactam Chemicals Ltd?
The Dividend Yield of Caprolactam Chemicals Ltd is 0.00 %.
What is the ROCE of Caprolactam Chemicals Ltd?
The ROCE of Caprolactam Chemicals Ltd is 0.48 %.
What is the ROE of Caprolactam Chemicals Ltd?
The ROE of Caprolactam Chemicals Ltd is 13.7 %.
What is the Face Value of Caprolactam Chemicals Ltd?
The Face Value of Caprolactam Chemicals Ltd is 10.0.